Nasdaq:US$40.98 (-0.83) | HKEX:HK$77.60 (+11.60) | AIM:£5.92 (+0.14)
2000
FOUNDED
680
SCIENTIFIC TEAM
BASED IN CHINA, US,
EUROPE & AUSTRALIA
520+
DEDICATED ONCOLOGY
COMMERCIAL TEAM
IN CHINA
10
IN-HOUSE DISCOVERED
CLINICAL STAGE DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
NDA SUBMITTED IN THE US &
MAA SUBMITTED TO THE EMA
~40
CLINICAL TRIALS
AROUND THE GLOBE
HCM
NASDAQ &
LONDON AIM

OUR SCIENCE

Our core research and development philosophy is to take a holistic approach and treat cancer and immunological diseases through multiple modalities and mechanisms. We have taken a science-focused approach to develop highly selective, potent and well-tolerated cancer therapies that are deliberately engineered to improve drug exposure and reduce off-target toxicities.

R&D Philosophy Pipeline Products

Events, Circulars And Forms


2021 Half-Year Financial Results 2021-07-28
Bank of America 2021 Innovative China Conference 2021-06-11 - 2021-06-11
Company Update: R&D, Commercial and ASCO Data 2021-05-26 - 2021-05-27